Gareth Walters Email

Chief Regulatory Officer . Synairgen

Current Roles

Employees:
28
Revenue:
$4.3M
About
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
Synairgen Address
Southampton General Hospital
Southampton, null

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.